FBXO16 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can stabilize proteins targeted for degradation. FBXO16 is an F-box protein that is part of the ubiquitin-proteasome system. By inhibiting the proteasome, MG132 could lead to an accumulation of proteins that are normally ubiquitinated and degraded by the complex that includes FBXO16, potentially disrupting FBXO16s ability to function properly in protein turnover. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is another proteasome inhibitor. Similar to MG132, its inhibition of the proteasome could indirectly inhibit FBXO16 by causing a build-up of proteins that FBXO16 would normally help ubiquitinate and degrade, thereby hindering its functional role. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor. It can lead to the accumulation of polyubiquitinated proteins, which could interfere with the normal function of FBXO16 as it plays a role in tagging proteins for proteasomal degradation. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is a proteasome inhibitor that could inhibit the degradation pathway in which FBXO16 is involved by preventing the turnover of substrates that FBXO16 targets, which could impair the function of FBXO16. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a proteasome inhibitor that can inhibit the degradation of proteins involved in the ubiquitin-proteasome system, where FBXO16 functions. This could indirectly inhibit FBXO16 by limiting its ability to tag substrates for degradation. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
As a proteasome inhibitor, Carfilzomib could indirectly inhibit FBXO16 by causing an accumulation of substrates that FBXO16 would typically ubiquitinate, potentially disrupting the proteins normal function. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib, a proteasome inhibitor, could prevent the degradation of proteins that FBXO16 targets for ubiquitination, indirectly inhibiting FBXO16 by disrupting its role in protein turnover. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib, by inhibiting the proteasome, can lead to the accumulation of ubiquitinated proteins, potentially inhibiting FBXO16s function in the ubiquitin-proteasome degradation pathway. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $127.00 $572.00 $4090.00 $20104.00 | 20 | |
Withaferin A, although not a traditional proteasome inhibitor, has been shown to disrupt proteasomal activity, which could interfere with FBXO16s role in protein ubiquitination and degradation. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $155.00 | 6 | |
Celastrol has been reported to inhibit proteasomal activity and could indirectly inhibit FBXO16 by causing a backlog of proteins that FBXO16 would normally help to degrade. | ||||||